Champions Oncology Stock Probability of Future Stock Price Finishing Under 5.05

CSBR Stock  USD 7.51  0.04  0.53%   
Champions Oncology's future price is the expected price of Champions Oncology instrument. It is based on its current growth rate as well as the projected cash flow expected by the investors. This tool provides a mechanism to make assumptions about the upside potential and downside risk of Champions Oncology performance during a given time horizon utilizing its historical volatility. Check out Champions Oncology Backtesting, Champions Oncology Valuation, Champions Oncology Correlation, Champions Oncology Hype Analysis, Champions Oncology Volatility, Champions Oncology History as well as Champions Oncology Performance.
To learn how to invest in Champions Stock, please use our How to Invest in Champions Oncology guide.
  
As of 12/21/2024, Price To Sales Ratio is likely to drop to 1.24. In addition to that, Price Earnings Ratio is likely to grow to -8.58. Please specify Champions Oncology's target price for which you would like Champions Oncology odds to be computed.

Champions Oncology Target Price Odds to finish below 5.05

The tendency of Champions Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current PriceHorizonTarget PriceOdds to drop to $ 5.05  or more in 90 days
 7.51 90 days 5.05 
about 66.96
Based on a normal probability distribution, the odds of Champions Oncology to drop to $ 5.05  or more in 90 days from now is about 66.96 (This Champions Oncology probability density function shows the probability of Champions Stock to fall within a particular range of prices over 90 days) . Probability of Champions Oncology price to stay between $ 5.05  and its current price of $7.51 at the end of the 90-day period is about 32.93 .
Given the investment horizon of 90 days Champions Oncology has a beta of -0.54 suggesting as returns on the benchmark increase, returns on holding Champions Oncology are expected to decrease at a much lower rate. During a bear market, however, Champions Oncology is likely to outperform the market. Additionally Champions Oncology has an alpha of 0.7765, implying that it can generate a 0.78 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta).
   Champions Oncology Price Density   
       Price  

Predictive Modules for Champions Oncology

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Champions Oncology. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Hype
Prediction
LowEstimatedHigh
2.647.7512.86
Details
Intrinsic
Valuation
LowRealHigh
2.067.1712.28
Details
Naive
Forecast
LowNextHigh
3.618.7213.83
Details
1 Analysts
Consensus
LowTargetHigh
7.968.759.71
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Champions Oncology. Your research has to be compared to or analyzed against Champions Oncology's peers to derive any actionable benefits. When done correctly, Champions Oncology's competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in Champions Oncology.

Champions Oncology Risk Indicators

For the most part, the last 10-20 years have been a very volatile time for the stock market. Champions Oncology is not an exception. The market had few large corrections towards the Champions Oncology's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Champions Oncology, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Champions Oncology within the framework of very fundamental risk indicators.
α
Alpha over Dow Jones
0.78
β
Beta against Dow Jones-0.54
σ
Overall volatility
0.77
Ir
Information ratio 0.15

Champions Oncology Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Champions Oncology for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Champions Oncology can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
Champions Oncology is way too risky over 90 days horizon
Champions Oncology appears to be risky and price may revert if volatility continues
The company reported the previous year's revenue of 50.16 M. Net Loss for the year was (7.28 M) with profit before overhead, payroll, taxes, and interest of 24.34 M.
Champions Oncology currently holds about 8.06 M in cash with (6.14 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.6.
Champions Oncology has a frail financial position based on the latest SEC disclosures
Roughly 26.0% of the company shares are held by company insiders
Latest headline from gurufocus.com: Q2 2025 Champions Oncology Inc Earnings Call Transcript

Champions Oncology Price Density Drivers

Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Champions Stock often depends not only on the future outlook of the current and potential Champions Oncology's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Champions Oncology's indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding13.5 M
Cash And Short Term Investments2.6 M

Champions Oncology Technical Analysis

Champions Oncology's future price can be derived by breaking down and analyzing its technical indicators over time. Champions Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Champions Oncology. In general, you should focus on analyzing Champions Stock price patterns and their correlations with different microeconomic environments and drivers.

Champions Oncology Predictive Forecast Models

Champions Oncology's time-series forecasting models is one of many Champions Oncology's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Champions Oncology's historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

Things to note about Champions Oncology

Checking the ongoing alerts about Champions Oncology for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Champions Oncology help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Champions Oncology is way too risky over 90 days horizon
Champions Oncology appears to be risky and price may revert if volatility continues
The company reported the previous year's revenue of 50.16 M. Net Loss for the year was (7.28 M) with profit before overhead, payroll, taxes, and interest of 24.34 M.
Champions Oncology currently holds about 8.06 M in cash with (6.14 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.6.
Champions Oncology has a frail financial position based on the latest SEC disclosures
Roughly 26.0% of the company shares are held by company insiders
Latest headline from gurufocus.com: Q2 2025 Champions Oncology Inc Earnings Call Transcript

Additional Tools for Champions Stock Analysis

When running Champions Oncology's price analysis, check to measure Champions Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Champions Oncology is operating at the current time. Most of Champions Oncology's value examination focuses on studying past and present price action to predict the probability of Champions Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Champions Oncology's price. Additionally, you may evaluate how the addition of Champions Oncology to your portfolios can decrease your overall portfolio volatility.